GT Biopharma Inc (GTBP)

$0.52 +0.01 (2.29%)
Market Cap 7.02M
Revenue (ttm) 0.00
Net Income (ttm) -13.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,130,600
Avg Vol 1,689,774
Day's Range N/A - N/A
Shares Out 10.64M
Stochastic %K 36%
Beta 1.17
Analysts Sell
Price Target $8.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 919 4040
Address:
315 Montgomery Street, 10th Floor, San Francisco, United States
MyLuckygirlWSB
MyLuckygirlWSB Feb. 3 at 8:21 PM
$GTBP made it 30,000 shares
0 · Reply
MyLuckygirlWSB
MyLuckygirlWSB Feb. 3 at 7:52 PM
$GTBP I just entered at the dip 26,000 shares Wish me luck
0 · Reply
Streax
Streax Feb. 3 at 3:59 PM
$GTBP time for a reversal? FDA news! $SPY $FAT $MIST $OPEN
1 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 3 at 2:58 PM
$GTBP 17,000 @ .618.🔒
0 · Reply
RyanTheScammer2
RyanTheScammer2 Feb. 3 at 2:40 PM
$GTBP this has got $15 written all over it 🔥
0 · Reply
onlyfactshere
onlyfactshere Feb. 3 at 2:18 PM
$GTBP low float I’ll take some here Starter pack of 1500 shares
0 · Reply
Tonyboner
Tonyboner Feb. 3 at 1:44 PM
$GTBP No more news for long time, and raise is on the cards, this sees 30c sooner than later mk this post.
0 · Reply
Tonyboner
Tonyboner Feb. 3 at 1:43 PM
$GTBP 26 million float
0 · Reply
Investing4Knowledge
Investing4Knowledge Feb. 3 at 1:37 PM
$GTBP - News out, could see explosion here at market open 👀
0 · Reply
DaBullRunner
DaBullRunner Feb. 3 at 1:36 PM
$GXAI just broke $2 again this could be BIG 💰💰💰 GOT in EARLY before the crowd👇 🚨SPRC🚨now getting in here BEFORE the crowd Here’s why👇 $GTBP watching
0 · Reply
Latest News on GTBP
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Feb 3, 2026, 8:30 AM EST - 15 hours ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Jan 15, 2026, 8:30 AM EST - 19 days ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Jan 15, 2026, 8:01 AM EST - 19 days ago

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Dec 19, 2025, 7:44 AM EST - 6 weeks ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 19, 2025, 8:00 AM EST - 2 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 2 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 6 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Aug 11, 2025, 7:00 AM EDT - 6 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GT Biopharma Appoints New Member to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 8 months ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025, 9:00 AM EDT - 9 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma Announces Exercise of Warrants

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 16, 2022, 8:01 AM EDT - 4 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

May 12, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Apr 11, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 28, 2022, 4:15 PM EDT - 4 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 21, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

MyLuckygirlWSB
MyLuckygirlWSB Feb. 3 at 8:21 PM
$GTBP made it 30,000 shares
0 · Reply
MyLuckygirlWSB
MyLuckygirlWSB Feb. 3 at 7:52 PM
$GTBP I just entered at the dip 26,000 shares Wish me luck
0 · Reply
Streax
Streax Feb. 3 at 3:59 PM
$GTBP time for a reversal? FDA news! $SPY $FAT $MIST $OPEN
1 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 3 at 2:58 PM
$GTBP 17,000 @ .618.🔒
0 · Reply
RyanTheScammer2
RyanTheScammer2 Feb. 3 at 2:40 PM
$GTBP this has got $15 written all over it 🔥
0 · Reply
onlyfactshere
onlyfactshere Feb. 3 at 2:18 PM
$GTBP low float I’ll take some here Starter pack of 1500 shares
0 · Reply
Tonyboner
Tonyboner Feb. 3 at 1:44 PM
$GTBP No more news for long time, and raise is on the cards, this sees 30c sooner than later mk this post.
0 · Reply
Tonyboner
Tonyboner Feb. 3 at 1:43 PM
$GTBP 26 million float
0 · Reply
Investing4Knowledge
Investing4Knowledge Feb. 3 at 1:37 PM
$GTBP - News out, could see explosion here at market open 👀
0 · Reply
DaBullRunner
DaBullRunner Feb. 3 at 1:36 PM
$GXAI just broke $2 again this could be BIG 💰💰💰 GOT in EARLY before the crowd👇 🚨SPRC🚨now getting in here BEFORE the crowd Here’s why👇 $GTBP watching
0 · Reply
premarketmaker
premarketmaker Feb. 3 at 1:33 PM
$GTBP Clearance!! 9M float FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 3 at 1:32 PM
$GTBP GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 3 at 1:27 PM
$GTBP dip at open and i'm buying 2,000 more.🤝
0 · Reply
kellymone2
kellymone2 Feb. 3 at 12:45 PM
$GTBP joined @ 0,56$ really like the setup here
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 3 at 6:54 AM
$GTBP Great piece that accurately captures GTBP's current position. So if you want to refresh your understanding of GTBP or learn about GTBP for the first time, this is essential reading. https://everyticker.com/quote/GTBP/analysis/gt-biopharma-trike-platform-advances-as-capital-constraints-threaten-clinical-execution-nasdaq-gtbp
0 · Reply
ThunderCoopersmith
ThunderCoopersmith Feb. 2 at 8:05 PM
$GTBP what’s the story here?
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 2 at 6:51 PM
$GTBP can't believe i missed that dip!!!😡 rushed home to grab what i could on lunch. +3,000 @ .5499.
0 · Reply
Tonyboner
Tonyboner Feb. 2 at 3:33 PM
$GTBP This is why it's tanking ! 22,686,349 Shares of Common Stock. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-292856
0 · Reply
gata2016
gata2016 Feb. 2 at 3:24 PM
$GTBP Did I miss news?
1 · Reply
Outcomes
Outcomes Jan. 30 at 10:23 PM
$IBRX ….just saw commercial on FoxBusiness promoting $GTBP
2 · Reply
Waterwing
Waterwing Jan. 30 at 1:48 AM
$GTBP
0 · Reply
NOCKNOCK
NOCKNOCK Jan. 28 at 8:51 PM
$GTBP is this thing ready to go yet...
1 · Reply